Angiosarcoma (AS) is a rare sarcoma subtype showing considerable clinicopathologic and genetic heterogeneity. Most radiation-induced AS show MYC gene amplifications, with a subset of cases harboring KDR, PTPRB, and PLCG1 mutations. Despite recent advances, the genetic abnormalities of most primary AS remain undefined. Whole-transcriptome sequencing was initiated in 2 index cases of primary soft tissue AS with epithelioid morphology occurring in young adults for novel gene discovery. The candidate abnormalities were validated and then screened by targeted sequencing and fluorescence in situ hybridization in a large cohort of 120 well-characterized AS cases. Findings were subsequently correlated with the status of KDR, PLCG1, MYC, and FLT4 gene abnormalities. The clinicopathologic relevance and prognostic significance of these genetic changes were analyzed by statistical methods. Concurrent CIC mutations and CIC rearrangements were identified in both index cases, with a CIC-LEUTX fusion detected in 1 case. Upon screening, an additional visceral AS in a young adult had a complex CIC rearrangement, whereas 6 others harbored only CIC mutations. All 3 CIC-rearranged AS cases lacked vasoformation and had a solid growth of round, epithelioid to rhabdoid cells, showing immunoreactivity for CD31 and Etsrelated gene and sharing a transcriptional signature with other round cell sarcomas, including CIC-rearranged tumors. Overall, CIC abnormalities occurred in 9% (9/98) of cases, affecting younger patients with primary AS, with an inferior disease-free survival. In contrast, PLCG1 and KDR mutations occurred in both primary and secondary AS cases, accounting for 9.5% and 7%, respectively, with a predilection for breast and bone/viscera location, regardless of MYC status. MYC amplification was present in most secondary AS related to breast cancer (91%) compared with other causes (25%) or primary AS (7%). FLT4amplified AS lacked PLCG1/KDR mutations, occurring predominantly in MYC-amplified population, and showed poor prognosis.
A ngiosarcomas (ASs) are mesenchymal tumors recapitulating endothelial cell differentiation and displaying variable degrees of vascular formation. 1 Although AS account for only 2% of soft tissue sarcomas, they have a highly aggressive behavior and dismal overall survival (OS). 2 The age range at diagnosis varies significantly, with a peak incidence in the seventh decade. AS is extremely rare in children and young adults, outside of the breast location. Furthermore, AS occurs in a wide range of anatomic sites, including skin (mainly head and neck and after radiation), breast, soft tissue, bone, and viscera. Although most AS present de novo, a significant number of patients develop AS secondary to radiotherapy and less commonly to chronic lymphedema or toxic carcinogens. Moreover, there is a broad spectrum of morphologic appearances, spanning from well-formed vasoformative spaces with minimal cytologic atypia to solid sheets of epithelioid or spindled cells lacking vasoformation. 1 Cytogenetically, most AS are characterized by complex karyotypes, without recurrent chromosomal changes being described. 3, 4 By gene expression profiling, AS shows distinctive upregulation of genes related to angiogenesis and endothelial cell receptors compared with other sarcoma types. 5, 6 Recurrent somatic mutations involving angiogenic signaling pathways, such as KDR, PTPRB, and PLCG1, have been identified in about 40% of AS cases, whereas only rare mutations were reported in RAS, PIK3CA, TP53, FLT4, and TIE1. [6] [7] [8] [9] PTPRB mutations with or without coexisting PLCG1 mutations have been reported exclusively in secondary or MYC-amplified AS. 8 In contrast, KDR mutations have been reported in both radiation-induced AS after breast cancer and primary AS (breast and heart). 6, 9 High level of MYC amplification is the hallmark of most postradiationassociated and chronic lymphedema-associated AS, with only a small subset of primary AS sharing this abnormality. [10] [11] [12] Analysis of MYC amplification by fluorescence in situ hybridization (FISH) or MYC expression by immunohistochemistry has been confirmed by a number of studies as a reliable ancillary technique to distinguish radiation-related AS from other radiationinduced conditions, particularly atypical vascular lesions. [11] [12] [13] [14] Despite this recent progress accelerated by the nextgeneration sequencing methodology, the underlying pathogenesis of most AS remains undefined, particularly of primary AS and AS occurring in younger patients. In this study we sought to investigate further novel genetic abnormalities by whole-transcriptome sequencing of 2 index cases of primary soft tissue AS displaying an epithelioid phenotype. The candidate abnormalities were then screened in a large and diverse cohort of AS spanning different clinicopathologic features and compared with other known genetic events, such as PLCG1/KDR mutations and MYC/FLT4 amplification.
MATERIALS AND METHODS

Patient Collection
The Department of Pathology files at Memorial Sloan Kettering Cancer Center, New York, were searched for cases diagnosed with AS. A total of 120 cases had adequate material available for further molecular analysis, with 62 cases being included in our prior studies. 6, 7, 11, 15 The diagnosis was confirmed by the presence of vasoformative features microscopically and/or by immunoreactivity for endothelial cell markers CD31 and Ets-related gene (ERG). The relevant clinical information and follow-up data were obtained from the electronic medical records. This study was approved by the Institutional Review Board 02-060.
RNA Sequencing and Data Mining using FusionSeq and Mutation Detection Algorithms
From 5 primary AS cases, including the 2 index cases (AS1 and AS2) of soft tissue epithelioid AS lacking vasoformative features and the remaining 3 cases with conventional histology (2 scalp [AS25 and AS32] and 1 breast [AS110]), RNA was extracted from frozen tissue and subjected to transcriptome sequencing. Total RNA was prepared in accordance with the standard Illumina mRNA sample preparation instructions. Paired-end RNA sequencing at read lengths of 50 or 51 bp was performed on the HiSeq 2000 platform. All reads were independently aligned with STAR alignment software against the human genome sequence (hg19) and a splice junction library, simultaneously. 16 The mapped reads were analyzed with the FusionSeq method to identify potential fusion transcripts. 17 Potential mutated genes were searched by MuTect (var 1.15) 18 and VarScan (var 2.3.8) 19 variant callers with the annotation added by the Variant Effect Predictor tool provided by Ensembl. The candidate fusion genes and mutations were validated subsequently.
Reverse Transcription-Polymerase Chain Reaction
An aliquot of the RNA extracted by Trizol Reagent (Invitrogen, Carlsbad, CA) was used to confirm the potential fusion transcripts. After cDNA synthesis by SuperScript III First-Strand Synthesis Kit (Invitrogen), polymerase chain reaction (PCR) was performed using the Clontech Advantage 2 PCR Enzyme System Kit (Clontech, Mountain View, CA) with the following primers: CIC exon 19 forward primer, 5 0 -CTGGTCATGCAGCTCTTTCA GG-3 0 , and LEUTX exon 3 reverse primer, 5 0 -GTGTC ATCTTCCCCTGGCAAGTC-3 0 . Amplified products were sent for sequencing confirmation.
Targeted Sequencing for Hotspot Mutations
Genomic DNA was extracted from frozen or formalin-fixed paraffin-embedded tissue following the phenol/ chloroform protocol or by using the QIAamp DNA FFPE Tissue Kit (Qiagen), respectively. On the basis of the RNA sequencing results and the reviewed literature, the hotspottargeted regions included CIC exons 5, 15, and 18 to 20, 20 PLCG1 exons 11 and 18, 8, 21 and KDR exons 15, 16, and 24. 6, 9 The products were amplified with the Clontech Advantage 2 PCR Enzyme System (see Supplemental Table  S1 , Supplemental Digital Content 1, http://links.lww.com/ PAS/A327 for PCR primers). All mutations were verified bidirectionally by Sanger sequencing.
Fluorescence In Situ Hybridization
FISH on interphase nuclei of tissue sections was performed by applying custom probes from bacterial artificial chromosomes (BACs) flanking or targeting CIC, MYC, and FLT4 genes (Supplemental Table S2 , Supplemental Digital Content 1, http://links.lww.com/PAS/ A327). BAC clones were chosen according to the UCSC genome browser and obtained from BACPAC sources of Children's Hospital of Oakland Research Institute (CHORI) (Oakland, CA). DNA from individual BACs was isolated and labeled with different fluorochromes in a nick translation reaction. The slides were pretreated, denatured, and hybridized by probes. After overnight incubation, the slides were serially washed and mounted with DAPI in an antifade solution. 22 Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score for gene rearrangement was interpreted when at least 20% of the nuclei showed a breakapart signal. Nuclei with incomplete set of signals were omitted. An amplification was defined as the presence of >10 signals (ratio to control centromeric probe >10) or tight clustered signals characteristic of homogenous staining regions, as previously described. 10, 15 Western Blotting for CIC Protein Expression Frozen tissue from the 2 index AS cases and 10 control samples, including 5 CIC wild-type AS, 2 CIC-DUX4-positive small blue round cell tumors (SBRCTs), and 3 gastrointestinal stromal tumors, were homogenized with Tissue Protein Extraction Reagent (Thermo Scientific, Waltham, MA) supplemented with protease inhibitors. Electrophoresis and immunoblotting were performed with the polyclonal anti-CIC antibody (ABN446, 1:1000; Millipore, Billerica, MA). A b-actin expression was used as reference with the monoclonal antiactin antibody (8H10D10, 1:10,000; Cell Signaling, Danvers, MA). Following hybridization with the secondary antibodies, the blots were incubated with Immun-Star horseradish peroxidase luminal/enhancer (Bio-Rad, Hercules, CA) and exposed onto Kodak Biomax MR Film (Eastman Kodak, Rochester, NY).
Statistical Analysis
Statistical analysis was conducted using SPSS software (version 20; IBM, New York, NY). The associations between the clinicopathologic factors and the genetic status were evaluated by Pearson w 2 test, Fisher exact test, or the Mann-Whitney U test according to the variable attribute. Disease-free survival (DFS) was measured from the date of surgery to the date of recurrence, and OS was measured from the date of surgery to last follow-up or death. Kaplan-Meier estimate was determined to calculate the DFS and OS, and the statistical significance of different variables was examined by the log-rank test. The significant parameters in the Kaplan-Meier analysis were subjected to multivariate Cox regression model to examine the statistical significance. Two-sided P-values were calculated, and P < 0.05 was considered significant for all statistical analyses.
RESULTS
The entire cohort consisted of 34 (28%) men and 86 (72%) women, with a mean age of 58 years at diagnosis (median, 62 y; range, 13 to 91 y). There were 73 (61%) primary and 47 (39%) secondary AS cases. The anatomic locations for primary AS included breast (22, 30%), head and neck (14, 19%) , extremity (12, 16%), viscera (11, 15%), trunk (9, 12%), and body cavity (5, 7%). Aside from the mammary and visceral cases, the remaining primary AS cases were classified into cutaneous (14, 19%) , soft tissue (18, 25%), and intraosseous (8, 11%) subtypes. Secondary AS occurred following radiation for breast cancer (33) or other tumors (9) , or in the setting of long-standing lymphedema (5) . The average interval between radiotherapy and AS diagnosis was 11.3 years (median, 8.5 y; range, 4 to 70 y). Secondary AS occurred in the breast/chest wall (35, 75%; 33 s/p radiation for breast cancer, 1 s/p radiation for hemangiomatosis, 1 with chronic lymphedema due to thoracic surgery), extremity (7, 15%), head and neck (2, 4%), internal organs (2, 4%), and trunk (1, 2%).
CIC Gene Rearrangements Identified in a Subset of Epithelioid AS in Young Adults, Lacking Vasoformative Features
The fusion candidate identified by FusionSeq analysis in AS1 was a novel intrachromosomal CIC-LEUTX fusion, the 2 genes being 2.5 Mb apart at the 19q13.2 locus with similar directions of transcription (Fig. 1A) .
The chimeric transcript was confirmed by reverse transcription-PCR and composed of CIC exon 20 in-frame fused to LEUTX exon 3 ( Fig. 1B) . Because of the close vicinity of CIC and LEUTX genes, a 3-color FISH assay was adopted with an additional PEPD gene probe, 6.2 Mb away from LEUTX. The result confirmed the CIC rearrangements, with a complex pattern (Fig. 1C) .
In AS2, the FusionSeq algorithm did not reveal a robust fusion candidate, although a few chimeric CIC-DUX4 reads were identified. The FISH break-apart assay confirmed the presence of CIC rearrangements, with small and constant gaps, typical for an intrachromosomal translocation ( Fig. 1D ) and similar to the complex pattern seen in AS1. The FISH fusion assay using CIC and DUX4 probes did not confirm a fused signal between these 2 genes (data not shown).
Forty-eight additional AS cases were screened by FISH for CIC gene abnormalities, with emphasis on young age, soft tissue location, and epithelioid morphology. One additional CIC rearrangement was found in a renal AS (AS3) from a 21-year-old woman. In fact, 2 of the 3 CIC-rearranged AS cases occurred in patients below 30 years (Table 1) . Morphologically, all 3 shared an epithelioid phenotype, composed of nests and solid sheets without identifiable vascular structures (Figs. 2A-D). The tumor cells ranged from a primitive small round to a polygonal appearance, with pale eosinophilic to amphophilic cytoplasm and vesicular nuclei with conspicuous nucleoli (Figs. 2A-C). AS3 showed a distinctive rhabdoid phenotype, with eccentric nuclei and paranuclear densely eosinophilic cytoplasm, arranged in a pseudoalveolar pattern ( Fig. 2D ). Despite brisk mitotic activity (> 10 MF/10 HPFs) and geographic areas of necrosis, none showed significant nuclear pleomorphism. Immunohistochemically, all 3 cases demonstrated diffuse and strong CD31 and ERG expression and focal cytokeratin reactivity (Figs. 2E, and F). The AS3 in addition showed CD34 positivity, whereas AS2 displayed focal membranous CD99 staining. S100 protein and desmin were negative in all cases. As AS3 showed loss of INI1 expression, raising the possibility of a proximal-type epithelioid sarcoma, further FISH analysis showed no SMARCB1 gene abnormalities (data not shown). 23 
CIC Missense Mutations Occur Preferentially in Primary AS of Younger Patients
The MuTect and VarScan algorithms applied on the RNAseq data identified coexistent missense CIC mutations in both index cases, but not in the remaining 3 AS cases with classic vasoformative morphology. AS1 harbored a CIC exon 15 mutation and AS2 a CIC exon 18 mutation, both being validated by Sanger sequencing in the tumor DNA but not present in the germline DNA extracted from normal tissue ( Fig. 1E ). As additional hotspot mutations were reported in oligodendroglioma, including CIC exons 5, 19, and 20, 24 we screened an additional 95 AS cases for these 5 exons by direct sequencing. The results showed an additional 6 cases carrying 7 different missense mutations ( Table 1 ). The mutations were distributed in CIC exons 15 and 18 to 20, but, in contrast to oligodendroglioma, no CIC mutations were identified in exon 5, the site of the highly conserved HMG (high-mobility group) box domain. AS6 had 2 synchronous CIC exon 19 mutations, and AS7 In total we identified 9 (9%) AS harboring various CIC alterations, including gene rearrangements and/or missense mutations, their clinicopathologic features being summarized in Table 1 . There were 4 male and 5 female patients, with a mean age of 41 years (vs. 59 y in CIC wild-type cases, P = 0.02). Soft tissue AS was the most common type affected by this abnormality, followed by visceral, cutaneous, and breast locations. All except 1 were primary AS, only 1 case being possibly related to radiation (AS5, spleen), having a remote history of chemoradiation for ovarian germ cell tumor 35 years earlier. Nevertheless, none of the AS cases with CIC alterations demonstrated MYC amplification. All except 1 lacked other genetic abnormalities; only 1 primary breast AS (AS4) showed coexisting CIC and PLCG1 mutations.
Aside from the index cases, there were 2 additional CIC-mutant AS cases displaying an epithelioid phenotype, with limited vasoformation: a deep-seated soft tissue AS from the neck in a 21-year-old man, harboring 2 distinct CIC mutations (AS6), and a cutaneous scalp AS bearing a homozygous CIC mutation (AS7) (Figs. 3A, B) . The remaining 4 cases with single heterozygous CIC mutations exhibited a more classic morphology, with well to moderately formed vascular channels and pleomorphic cytology (Figs. 3C, D) . The breast AS with concurrent PLCG1 and CIC mutations demonstrated well-differentiated anastomosing vascular channels (Fig. 3D) . Thus, 3 of 6 (50%) AS cases presenting outside the breast location in adults below 30 years showed the presence of CIC gene abnormalities.
CIC-rearranged AS Show Upregulation of PEA3 Family of Transcription Factors and Overexpression of CIC Protein
By unsupervised hierarchical clustering of RNA sequencing data of >100 cases of various sarcoma types, the 2 index AS cases with CIC gene rearrangements showed an overlapping gene signature with a group of SBRCTs, including CIC-DUX4-positive cases (data not shown). Remarkably, there was a significant overexpression of the PEA3 family of ETS genes, such as ETV1, ETV4, and ETV5, as well as WT1 and VGF, commonly seen in the CIC-DUX4 signature of SBRCT ( Fig. 4A and Supplemental Table S3 , Supplemental Digital Content 1, http://links.lww.com/PAS/A327). [25] [26] [27] In addition, only a modest upregulation of angiogenesis and endothelial-related genes, such as TIE1, FLT4, and PECAM1 (CD31), were noted.
The western blot revealed high CIC protein expression in the 2 index AS cases, at similar levels as the 2 CIC-DUX4-positive SBRCTs, whereas the control group of conventional AS and gastrointestinal stromal tumors showed low, if any, protein levels (Fig. 4B ).
PLCG1/KDR Mutations are Mutually Exclusive But Occur in Similar AS Subsets
A total of 11 (9.5%) AS cases harbored PLCG1 mutations of the 116 informative cases (Supplemental Table S4 , Supplemental Digital Content 1, http://links. lww.com/PAS/A327). All except 1 occurred in women, with a mean age of 53 years (range, 23 to 82 y). The PLCG1-mutated AS cases were evenly distributed among primary (6 cases) and secondary AS (5 cases) types, the latter being all related to radiation for breast cancer. Among the primary AS cases there were 4 mammary and 2 visceral, 1 each in the heart and spleen. Most PLCG1 mutations (9, 82%) occurred in exon 18 (p.R707Q, 8; p.R707L), affecting the autoinhibitory Src homology 2 (cSH2) domain, with only 2 in exon 11 (p.S345F), within the PLCx catalytic domain. Both PLCG1 p.S345F mutations occurred in primary AS, 1 each in breast and spleen. These mutations were mutually exclusive from KDR mutations, but all 5 PLCG1-mutated secondary AS cases showed coexistent MYC amplifications. Histologically, the PLCG1-mutated AS exhibited a wide morphologic spectrum, ranging from well-formed vascular spaces to solid sheets of spindled to epithelioid endothelial cells, with low-grade to high-grade nuclear features.
KDR missense mutations were found in 8 (7%) of 113 informative cases ( Supplemental Table S4 , Supplemental Digital Content 1, http://links.lww.com/PAS/A327), seen exclusively in female patients (mean age, 56 y; range, 23 to 77 y). Five KDR mutations occurred in primary breast AS domain) in 1 case. In keeping with our previous study, KDR-mutated AS demonstrated a wide spectrum of lowgrade to high-grade phenotype, with variable vasoformation and solid growth. 6 As both KDR and PLCG1 genes are involved in the vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathway, it is not surprising that activating KDR/PLCG1 mutations are present in similar AS subsets, such as primary or secondary breast AS (15/52, 29%) and bone/viscera (3/19, 16%) locations (P = 0.012).
MYC and FLT4 Amplifications Occur Preferentially in AS Related to Breast Cancer Radiotherapy
The status of MYC gene copy number abnormalities was analyzed by FISH in 112 informative cases. MYC gene amplification was identified in 39 cases. It was detected in the overwhelming majority of AS cases secondary to radiation for breast cancer (28/31, 90%) and in AS related to chronic lymphedema (4/4, 100%). The incidence was significantly lower in AS secondary to radiation for other tumor types (2/8, 25%), such as lymphoma, hemangiomatosis, salivary gland carcinoma, germ cell tumor, and prostatic cancer. The lowest incidence was seen in primary AS (5/69, 7%), occurring only in breast, bone, soft tissue, and skin. MYC amplification was significantly associated with female sex (P = 0.002) and older age (P < 0.001), most likely related to the high frequency of AS related to radiation for breast cancer and the lag time of postradiation sarcoma. FLT4 copy number status was also assessed in 110 cases, showing gene amplifications in 6 AS cases (5.5%), all except 1 being coamplified with MYC (5/39 vs. 1/71, P = 0.022). All except 1 FLT4-amplified case occurred in secondary AS related either to radiation therapy for breast cancer or to lymphedema. Only 1 case occurred in a primary scalp cutaneous AS. None of them had PLCG1/KDR mutations. Histologically, FLT4-amplified AS exhibited mostly a solid, high-grade histology with variable epithelioid and spindled cell phenotype.
A summary of all molecular findings is depicted in Supplemental Figure S1 
Survival Analysis
Among 108 cases with follow-up information, the median follow-up duration was 27.3 months (range, 0.3 to 234 mo). Tumor recurrence occurred in 67 cases (70%), at a median disease-free duration of 16 months. Fifty patients (46%) died of disease, and the median OS duration was 55 months (95% confidence interval [CI], 37.1-72.3), with a 5-year survival rate of 44.5%. Among the different anatomic locations, the intraosseous/visceral AS showed the shortest OS (P < 0.001, a median 22 mo for intraosseous AS and 10 mo for visceral AS) (Supplemental Table S5 , Supplemental Digital Content 1, http://links. lww.com/PAS/A327). Secondary AS and the presence of CIC alterations conferred an inferior DFS and remained statistically significant by multivariate Cox regression (P = 0.007; hazard ratio, 2.691; 95% CI, 1.314-5.512; P = 0.006; hazard ratio, 3.462; 95% CI, 1.419-8.443, respectively). The presence of MYC amplification had only a trend toward worse DFS (P = 0.083) and OS (P = 0.062), but the presence of FLT4 amplification was associated with a short OS (P = 0.037).
DISCUSSION
Despite significant progress being made on the discovery of molecular abnormalities driving AS pathogenesis, the pace of further understanding is hindered by the broad clinical and pathologic heterogeneity of this disease. Even at the molecular level, AS emerges as a multifaceted disease, with mostly nonoverlapping genetic signatures across clinical subsets; the majority of the alterations described to date, such as MYC/FLT4 amplifications and PLCG1/ PTPRB mutations, affect secondary AS. Although at the gene expression level, AS subtypes share a distinct transcriptional profile with upregulation of angiogenic factors and endothelial receptors, compared with other tumor types, 1, 2, 5, 6 this feature is most likely reflective of its line of differentiation rather than of overlapping oncogenic driver events. Particularly limited knowledge surrounds primary AS, such as in cutaneous or soft tissue locations, where no recurrent mutations have been identified to date. Furthermore, no insight has been gained in AS occurring in younger patients, which are often highly aggressive and exhibit a high-grade epithelioid or spindled phenotype with scarce vasoformative features. 28 Thus, our study focused on these orphan subsets, taking advantage of 2 index cases of primary soft tissue AS occurring in young patients with available material for paired-end RNA sequencing. The results are remarkable with identification of similar CIC gene rearrangements coexisting with CIC mutations in both cases. The extended screening further identifies a renal AS in a young patient with CIC gene rearrangements by FISH, as well as an additional 6 cases with missense mutations. In total, CIC alterations were detected in 9% of AS cases showing a predilection for young patients and lacking MYC/FLT4 amplifications. CIC, a human homolog of the Drosophila gene capicua, belongs to the HMG-box family. 29 CIC binding to target promoters and enhancers suppresses transcription in the absence of signaling. The activation of CIC protein through phosphorylation results in either attenuation of CIC DNA binding activity or prevents its nuclear import, relieving the default inhibitory ability of CIC. [30] [31] [32] CIC gene abnormalities have been described in a variety of cancers, such as oligodendroglioma, medulloblastoma, breast cancer, and SBRCTs. 20, 25, [33] [34] [35] CIC-related fusions account for two-thirds of EWSR1negative SBRCTs, with the CIC-DUX4 fusion exhibiting high chimeric CIC protein expression and an enhanced transcriptional activity of CIC downstream targets, including the PEA3 family genes, such as ETV1, ETV4, and ETV5. 25, 35 Remarkably, the 2 index AS cases harboring CIC rearrangements shared the gene signature of CIC fusion-positive SBRCTs, with upregulation of ETV1, ETV4, and ETV5 genes. Moreover, the CIC fusion partners LEUTX and DUX4 belong to the same class of paired (PRD) homeobox genes, 36 and KAT6A-LEUTX fusion has been reported in a therapy-related case of acute myeloid leukemia. 37 A high frequency (69% to 78%) of homozygous CIC mutations has been reported in oligodendrogliomas with 1p/19q deletion. 20, 38, 39 The biallelic CIC inactivation caused by mutation and deletion also results in upregulation of the CIC-targeted genes (ETV1, ETV4, ETV5, and CCND1). 27 Most CIC mutations reported in oligodendroglioma occur in the HMG domain or are proteintruncating mutations. In contrast, CIC mutations identified in AS clustered in exons 18 to 20 (single, double, or homozygous mutations), targeting the nuclear localization and repressor activity of the CIC protein. 29 These findings bring forward an underappreciated disconnect between tumor differentiation and pathogenesis. On one hand, the 2 index AS cases expressed all markers of endothelial lineage (CD31, ERG), whereas on the other hand they displayed the gene signature characteristic of its driving genetic abnormality, the CIC rearrangement, with upregulation of PEA3 transcription factors. A somewhat similar example in a different vascular tumor type is the TFE3 fusion-positive epithelioid hemangioendothelioma, where the endothelial lineage markers are expressed despite the oncogenic activation of the TFE3 gene signature. 40 As these concepts evolve, it remains to be determined whether the therapy of these CIC-rearranged AS should target the line of differentiation-that is, endothelial receptors-using cytotoxic therapy or VEGFR inhibitors typically used for conventional AS, or target the PEA3-transcriptional signature, thus being managed with Ewing sarcoma-type protocols. The latter approach seems to be more in keeping with today's "basket trials" strategy, enrolling patients based on their specific genetic alterations rather than the histologic type.
In a recent study, Behjati et al 8 identified PTPRB and PLCG1 in 26% of AS cases, being restricted to radiation-associated/MYC-amplified AS. The 3 PLCG1 mutations (p.R707Q) coexisted with PTPRB mutations and occurred in 9% of AS cases tested. The same PLCG1 hotspot mutation was subsequently identified in 3 of 10 cardiac AS cases tested. 9 A different PLCG1 missense mutation (p.S345F) was also more recently reported in cutaneous (19%) and nodal (13%) peripheral T-cell lymphoma. 21, 41 Our study screened a large cohort of AS cases for both hotspots and found 11 (9.5%) PLCG1-mutated cases, confirming that p.R707Q mutation occurs in both primary (breast, heart) and secondary AS. Our results also show PLCG1 p.S345F in 2 primary AS cases (breast and spleen), a previously unreported finding. PLCG1 encodes phospholipase Cg1 (PLCg1), a member of the phosphatidylinositol-specific phospholipase-C (PI-PLC) family, which generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol, triggering Ca 2+ -dependent signaling and protein kinase C activation, respectively. The p.S345F mutation alters the PLCx protein catalytic domain, thus activating the downstream calmodulin/calcineurin signaling by facilitating the interaction with lipids and its phosphodiesterase activity. 21 In contrast, the codon 707 mutation maps at the c-terminal Src homology 2 (cSH2) domain 8, 9 ; mutations at this site preventing the intramolecular interaction of phosphorylated PLCg1 and triggering constitutive activation of diacylglycerol and IPdependent signaling.
In our previous study, we reported activating KDR mutations in 10% of AS cases, being identified only in primary breast or secondary AS after breast cancer. 6 Kunze et al 9 reported 2 cases of cardiac AS harboring KDR mutations, one each in the extracellular immunogloulin domain (R720W) and transmembrane domain (T771K). The present investigation identifies 4 new cases (7% in total), including 1 case arising in the vertebral bone. The most common hotspot was KDR codon 771 in exon 16 (transmembrane domain, 5 cases), followed by KDR codons 717 and 731 in exon 15 (extracellular domain Ig-like C2 type 7, 2 cases) and KDR exon 24 codon 1065 (kinase domain, 1 case). Our results also show that KDR and PLCG1 mutations, accounting for 17% of AS cases, are mutually exclusive and evenly distributed among primary and secondary AS cases, mainly affecting breast and only occasionally present in bone or viscera, with no impact on morphology or outcome. Both KDR and PLCG1 mutations share a common VEGFR2/PLCg1 signaling pathway. KDR, also known as VEGFR2, is a member of the human VEGFR family of receptor tyrosine kinases (VEGFR1-3), with critical regulatory functions in vasculogenesis and angiogenesis upon binding to various VEGFs. 42, 43 Although activating KDR mutations are relatively rare in AS, KDR is universally overexpressed in AS 6 through alternative yet undefined mechanisms. Therapy with anti-VEGFR agents, such as sorafenib, which targets VEGFR2 and Ras kinase, 43 has shown limited antitumor activity. 44 An alternative mechanism of VEGFR activation in secondary AS is the presence of FLT4 (a.k.a. VEGFR3) amplification, which mostly occurs in association with MYC amplification. 11, 14 FLT4 amplification was identified in 13% (5/39) of MYC-amplified AS cases, mutually exclusive from KDR/PLCG1 mutations, and associated with a poor outcome. All except 1 FLT4-amplified secondary AS occurred in the breast/chest wall area, being coamplified with MYC. Only 1 case of a primary scalp AS had FLT4 amplification in the absence of MYC abnormalities by FISH. A recent study suggested that diffuse and strong cytoplasmic FLT4 immunostaining is a potential surrogate ancillary test for FLT4 gene amplification by FISH. 14 MYC deregulation is a well-known oncogenic event involving a wide array of human cancers, lying at the crossroads of diverse signal transduction pathways, including cell growth, metabolism, differentiation, transformation, cell cycle, and angiogenesis. 45 High-level MYC amplification at the 8q24.21 locus was first shown by Manner et al 10 in 55% of secondary AS cases using array-comparative genomic hybridization. Subsequently, larger studies showed that MYC amplification is the hallmark of radiation-induced AS, occurring in the majority of secondary AS but not in other radiation-related sarcomas or atypical vascular lesions. 11, 13 However, more recent studies identified MYC amplification in rare cases of primary AS, including breast, bone, viscera, and skin. 4, 12, 15, 46 Compared with FISH assay, the immunohistochemical analysis detects a higher number of MYC overexpression in primary AS. 12, 46 Our findings support prior results of MYC amplification in a small subset (7%) of primary AS, encompassing breast and somatic soft tissue. In contrast, MYC amplification occurs in 91% of secondary AS related to breast cancer radiation or lymphedema.
In conclusion, this is the largest molecular investigation to date of a diverse cohort of 120 AS patients. We describe recurrent, novel, CIC gene rearrangements in a subset of young adults with primary soft tissue and visceral AS, with or without concurrent CIC mutations, associated with upregulation of CIC-target genes, such as ETV1, ETV4, and ETV5. An additional subset of AS harbored only missense CIC mutations, occurring with predilection in younger patients with primary AS and being associated with a highly aggressive clinical course. The mutually exclusive KDR/PLCG1 mutations were present in both primary and secondary AS but restricted to breast, bone, and viscera, with no histologic or prognostic correlates. Our results show that, in total, the CIC, PLCG1, KDR, MYC, and FLT4 genetic abnormalities account for around 50% of our study cohort. However, our study did not examine abnormalities in PTPRB, TP53, RAS, PIK3CA, etc., as described in other studies. [7] [8] [9] Hence, the molecular alterations of a significant number of cases remain to be elucidated. The divergent genetic abnormalities emerging in different AS subsets promise both challenges and opportunities in designing future clinical trials of targeted therapy in this disease.
